The EMA Committee on Human Medicines (CHMP) announced that it has approved two additional production sites for Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.
One factory is located in Reinbek, Germany, operated by Allergopharma GmbH & Co. KG. and the other in Stein, Switzerland and is managed by Novartis Pharma.
The two production lines will carry out final product manufacturing steps at different stages of the process and are expected to support Comirnaty’s ongoing supply to the European Union.
This recommendation does not require an additional decision of the Commission and the production lines can be put into operation immediately.